Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 1
Sponsor overview
University of Arizona
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT04820179 | https://clinicaltrials.gov/study/NCT03602066
Assets
Linked programs
- Cabozantinib + Atezolizumab: Watchlist Signal (2/5)
- Chlorine Dioxide Sterilization: Registry Stop Signal (3/5)